Fly News Breaks for December 13, 2019
Dec 13, 2019 | 05:35 EDT
Credit Suisse analyst Evan Seigerman downgraded Neurocrine Biosciences to Neutral from Outperform with an unchanged price target of $110. The analyst says the stock's current valuation fully reflects his above-consensus estimates for Ingrezza. Pipeline diversification will likely be needed for share outperformance, Seigerman tells investors in a research note.
News For NBIX From the Last 2 Days
There are no results for your query NBIX